Cardiac Disease Events Up in Metabolically Healthy Obese

Share this content:
Cardiac Disease Events Up in Metabolically Healthy Obese
Cardiac Disease Events Up in Metabolically Healthy Obese

TUESDAY, Sept. 12, 2017 (HealthDay News) -- Metabolically healthy obese individuals have increased risk of coronary heart disease, cerebrovascular disease, and heart failure compared with normal-weight individuals, according to a study published in the Sept. 19 issue of the Journal of the American College of Cardiology.

Rishi Caleyachetty, M.B.B.S., Ph.D., from the University of Birmingham in the United Kingdom, and colleagues examined the correlations among metabolically healthy obese individuals and four different presentations of incident cardiovascular disease in a cohort of 3.5 million individuals, aged 18 years or older, using electronic health records in The Health Improvement Network. Body size phenotypes were created, defined by body mass index categories (underweight, normal weight, overweight, and obese), and three metabolic abnormalities (diabetes, hypertension, and hyperlipidemia) were assessed.

The researchers found that, compared with normal-weight individuals with no metabolic abnormalities, obese individuals with no metabolic abnormalities had a higher risk of coronary heart disease, cerebrovascular disease, and heart failure during a mean follow-up of 5.4 years (multivariate-adjusted hazard ratios, 1.49, 1.07, and 1.96, respectively). With increasing number of metabolic abnormalities, the risk of coronary heart disease, cerebrovascular disease, and heart failure increased in normal weight, overweight, and obese individuals.

"Metabolically healthy obese individuals had a higher risk of coronary heart disease, cerebrovascular disease, and heart failure than normal weight metabolically healthy individuals," the authors write. "Even individuals who are normal weight can have metabolic abnormalities and similar risks for cardiovascular disease events."

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »